NASDAQ · ASRT
Healthcare · Drug Manufacturers - Specialty & Generic
$23.50
Up+$0.00 (+0.00%)
Updated Aug 24, 2026, 8:51 AM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
ASRT does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning ASRT.
ASRT research
Company profile and research snapshot.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 13, 2026 | Lake Street | Hold | — |
| May 5, 2026 | HC Wainwright & Co. | Neutral | — |
| Apr 9, 2026 | Lake Street | Hold | — |
| Apr 9, 2026 | HC Wainwright & Co. | Neutral | — |
| Jan 5, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Finnhub · Apr 13, 2026
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed sale of Assertio Holdings, Inc. to Garda Therapeutics. Under...
Benzinga · Apr 9, 2026
Lake Street analyst Thomas Flaten downgrades Assertio Hldgs (NASDAQ:ASRT) from Buy to Hold and lowers the price target from $45 to $18.
Benzinga · Apr 9, 2026
Wall Street analysts changed outlook on top names. See rating changes on our analyst ratings page. Find out what analysts think of ZS stock.
Benzinga · Apr 9, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Assertio Hldgs (NASDAQ:ASRT) from Buy to Neutral and lowers the price target from $35 to $18.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ASRT.
